SARS-CoV-2対策mRNAワクチンの課題と機会<br>Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 : A Multidisciplinary Perspective

個数:1
紙書籍版価格
¥38,294
  • 電子書籍

SARS-CoV-2対策mRNAワクチンの課題と機会
Challenges and Opportunities of mRNA Vaccines Against SARS-CoV-2 : A Multidisciplinary Perspective

  • 著者名:Mueller, Siguna
  • 価格 ¥28,949 (本体¥26,318)
  • Springer(2023/01/04発売)
  • ポイント 263pt (実際に付与されるポイントはご注文内容確認画面でご確認下さい)
  • 言語:ENG
  • ISBN:9783031189029
  • eISBN:9783031189036

ファイル: /

Description

This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy.

This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general. 

Table of Contents

Chapter 1: Introduction.- Part I: Scientifi Underpinnings, early expectations, and emerging challenges from the global inoculation experience.- Chapter 2: Appraisal of Some of the Key Postulates Underlying mRNA Vaccines.- Chapter 3: Relevance for mRNA vaccine safety.- Chapter 4: From Challenges to Opportunities and Open Questions.- Chapter 5: The challenge of evaluating vaccine safety and effectiveness.- Chapter 6: Safeguarding against the analog of antimicrobial-resistance development.- Chapter 7: Scales, pseudoscales, the human factor, and a way forward.- Part II: A deeper dive into mRNA vaccine safety and security, and developments until Delta.- Chapter 8: mRNA Vaccine safety and efficacy - official criteria when AEs are caused by the injection.- Chapter 9: mRNA Covid-19 vaccines best reflect effective pharmaceuticals - basic considerations and LNPs.- Chapter 10: mRNA Covid-19 pharmaceuticals and the spike antigen.- Chapter 11: Other facets of SARS-CoV-2 immunity, the risk of immune tolerance and T cell exhaustion.- Part III: The Omicron variants.- Chapter 12: Omicron.- Chapter 13: Conclusion.

最近チェックした商品